

Press Release

Matthias Link
Corporate Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2872
F +49 6172 608-2294
matthias.link@fresenius.com
www.fresenius.com

August 28, 2020

Annual General Meeting: Stable business model proves its strength; 27th consecutive dividend increase approved

Fresenius remains on course for growth, even in the face of significant challenges presented by the COVID-19 pandemic. This was confirmed by Chief Executive Officer Stephan Sturm at the global healthcare group's Annual General Meeting today. Originally scheduled for May, the AGM was held as a virtual meeting on the Internet in order to protect the health of all participants.

In his speech to shareholders, Sturm underlined Fresenius' important role in the current situation: "We are needed – more than ever. We help ensure that healthcare systems around the world can continue to function. Even in a crisis such as this. We are doing everything we can to provide the best possible care for patients. This is our responsibility, and we will fulfill it. I am proud of that."

Despite the strains caused by the pandemic and the additional effort required, Sturm confirmed the company's medium-term outlook for 2020 to 2023. Sales growth is expected to increase by an annual average of 4 to 7 percent and net income growth¹ by an annual average of 5 to 9 percent over this period. "We will grow somewhat less than planned this year due to the coronavirus," said Sturm. "This must be compensated for in the coming years. I believe we are on the right path. There is no reason to diverge from this goal. The need for high-quality

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA

medicine is increasing worldwide. We offer high-quality medicine. We want to serve this demand, and we can. That is why we will continue to be successful.”

Shareholders approved with a large majority of 99.99 percent the proposal of the General Partner and the Supervisory Board to increase the dividend for the 27th consecutive time. It was raised by 5 percent, to €0.84 per share.

Shareholder majorities of 99.68 percent and 85.14 percent, respectively, approved the actions of the Management and Supervisory Boards in 2019.

At the virtual Annual General Meeting, 73 percent of the subscribed capital was represented.

#

Fresenius is a global health care group, providing products and services for dialysis, hospital and outpatient medical care. In 2019, Group sales were €35.4 billion. On June 30, 2020, the Fresenius Group had 302,846 employees worldwide.

For more information visit the Company’s website at www.fresenius.com.
Follow us on social media: www.fresenius.com/socialmedia

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Sturm (Chairman), Dr. Francesco De Meo, Rachel Empey,
Mats Henriksson, Rice Powell, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick